Simultaneous HPLC Determination of Metronidazole and Spiramycin in Plasma and Brain of Mouse

Author(s): Chew W. Kit, Ignacio Segarra

Journal Name: Current Pharmaceutical Analysis

Volume 7 , Issue 4 , 2011

Become EABM
Become Reviewer
Call for Editor


Treatments fail to eliminate Toxoplasma gondii due to low drug brain penetration. Spiramycin is an Mrp2, Pglycoprotein substrate, active in acute and chronic murine toxoplasmosis. Metronidazole is a CYP3A4 inhibitor and Pglycoprotein substrate. We developed a simple HPLC method to analyze spiramycin and metronidazole simultaneously. Male Balb/c mice were randomly selected in three groups and were dosed orally either 500 mg/kg metronidazole (group 1, n=4) or 400 mg/kg spiramycin (group 2, n=4) or coadministered 500 mg/kg metronidazole 30 min prior to 400 mg/kg spiramycin (group 3, n=4). Mice were euthanized 2 hours after spiramycin administration. Metronidazole and spiramycin brain and plasma concentrations were measured by HPLC using a Phenomenex® C-18 (150x3.8 mm, 5 μm) column and acetonitrile-phosphate buffer (pH 2.5) gradient elution (20/80 to 30/70 in 3 min) at 1 mL/min flow, 29°C and 232 nm. The method was linear (0.25-50.0 μg/mL), the LLOQ was 0.25 μg/mL, intra- and interday variability, precision and accuracy were within 15%. Recoveries were above 75% and there was no matrix interference. Metronidazole eluted at 3 min and spiramycin at 5 min. Spiramycin did not affect plasma metronidazole concentration (6.93±0.48 μg/mL in combination vs. alone 7.65±0.55 μg/mL) or brain (2.96±0.60 μg/g after coadministration vs. control, 4.02±0.78 μg/g). Metronidazole did not change spiramycin plasma concentration (coadministration: 3.94±1.30 μg/mL, control: 3.71±0.94 μg/mL). However, spiramycin brain concentration increased 2-fold after metronidazole coadministration from 2.44±0.33 μg/g to 4.83±1.25 μg/g (P < 0.05). Metronidazole increased spiramycin brain uptake, probably due to P-glycoprotein inhibition, which may improve toxoplasmosis encephalitis treatments.

Keywords: Brain uptake, Drug-drug interaction, Metronidazole, Spiramycin, Toxoplasma gondii, CYP3A4 inhibitor, HPLC, LLOQ, Plasma, Acute murine toxoplasmosis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [262 - 267]
Pages: 6
DOI: 10.2174/157341211797458032
Price: $65

Article Metrics

PDF: 7